Effect of Fusobacterium necrophorum leukotoxoid vaccine on susceptibility to experimentally induced liver abscesses in cattle.
The efficacy and the optimum dose of Fusobacterium necrophorum crude leukotoxoid vaccine required to immunize and protect steers against experimentally induced liver abscesses were evaluated. The vaccine consisted of cell-free culture supernatant of a high leukotoxin-producing strain of F. necrophorum, inactivated with formalin and homogenized with an adjuvant. Twenty-five steers were assigned randomly to the following five treatment groups: control; three doses (1.0, 2.0, and 5.0 mL) of the culture supernatant; and 2.25 mL of the concentrated supernatant (equivalent to 5 mL of the original supernatant). Vaccine was injected subcutaneously on d 0 and 21. Blood samples were collected weekly to monitor antileukotoxin antibody titers. Three weeks after the second vaccination (d 42), all steers were injected intraportally with F. necrophorum culture to induce liver abscesses. Three weeks later (d 63), steers were euthanatized and necropsied; livers were examined and protection assessed. Antileukotoxin antibody titers in the control steers generally did not differ from the baseline (wk 0) titers. The titers in the vaccinated groups increased, more so after the second injection, and the increase was generally dose-dependent. Necropsy examination revealed that all steers in the control group had abscesses in the liver. In the vaccinated groups, two of five steers in the 1.0-mL group and one each in the 2.0-, 5.0-, and 2.25-mL (concentrated) groups had liver abscesses. Antileukotoxin antibody titers were higher (P < .05) in steers that did not develop abscesses than in steers that developed abscesses. The difference suggested a protective effect of antileukotoxin antibodies against experimentally induced liver abscesses.
Saginala
S
S
Department of Animal Sciences, Kansas State University, Manhattan 66506, USA.
Nagaraja
T G
TG
Lechtenberg
K F
KF
Chengappa
M M
MM
Kemp
K E
KE
Hine
P M
PM
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology / Q000378:metabolism; D001428:Bacterial Vaccines / Q000276:immunology / Q000494:pharmacology*; D002417:Cattle; D002418:Cattle Diseases / Q000209:etiology* / Q000382:microbiology / Q000517:prevention & control*; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000662:veterinary; D005098:Exotoxins / Q000276:immunology / Q000494:pharmacology*; D005675:Fusobacterium necrophorum / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology*; D007114:Immunization / Q000379:methods / Q000662:veterinary; D007166:Immunosuppressive Agents / Q000276:immunology / Q000494:pharmacology*; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008100:Liver Abscess / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D008297:Male
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D005098:Exotoxins; D007166:Immunosuppressive Agents; C018579:leukotoxin